The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
第三代 AKR1C3 激活的前药 ACHM-025 可根除侵袭性 T 细胞急性淋巴细胞白血病的临床前模型中的疾病
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-024-01180-x
Toscan Cara E, McCalmont Hannah, Ashoorzadeh Amir, Lin Xiaojing, Fu Zhe, Doculara Louise, Kosasih Hansen J, Cadiz Roxanne, Zhou Anthony, Williams Sarah, Evans Kathryn, Khalili Faezeh, Cai Ruilin, Yeats Kristy L, Gifford Andrew J, Pickford Russell, Mayoh Chelsea, Xie Jinhan, Henderson Michelle J, Trahair Toby N, Patterson Adam V, Smaill Jeff B, de Bock Charles E, Lock Richard B
